⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4570475 | 0.76 | — | — | |
| SCHEMBL31149394 | 0.75 | — | — | |
| SCHEMBL332742 | 0.75 | — | — | |
| SCHEMBL30421035 | 0.75 | — | — | |
| SCHEMBL232870 | 0.75 | — | — | |
| SCHEMBL907794 | 0.75 | — | — | |
| SCHEMBL621291 | 0.75 | — | — | |
| SCHEMBL8150851 | 0.75 | — | — | |
| SCHEMBL29818515 | 0.75 | — | — | |
| SCHEMBL3370156 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0139522-B1 | METHOD FOR CONTROLLING TERMITES | THE DOW CHEMICAL COMPANY (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0139522-A1 | Method for controlling termites | THE DOW CHEMICAL COMPANY (US) | 1985-05-02 | — | — | EP | claimed |
| EP-4720040-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024246522-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | LARIO THERAPEUTICS LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| CN-112469720-B | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11731961-B2 | Phenyl propionic acid derivatives and uses thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-22 | — | — | US | disclosed |
| EP-3784671-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-9994558-B2 | Multicyclic compounds and methods of using same | Karyopharm Therapeutics Inc. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015042414-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USING SAME | Karyopharm Therapeutics Inc. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-5629428-A | 3-Chloropyridines, and their use in liquid-crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-13 | — | — | US | disclosed |